All 1 tracked stories fall under one category: market-trends. Nasdaq is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The average consequence score is 6, matching the 6 beat baseline for this window. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about U.S. Drug Enforcement Administration (DEA)
All 1 tracked stories fall under one category: market-trends. Nasdaq is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The average consequence score is 6, matching the 6 beat baseline for this window. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. U.S. Drug Enforcement Administration (DEA) appears in 1 tracked Healthcare story from July 27, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering U.S. Drug Enforcement Administration (DEA). Shared-story counts are live from our verified record — not editorial picks.
SNDL’s completion of the Parallel asset acquisition gives it indirect control of medical cannabis operations in three states, positioning the company to directly expand patient access and standardize products once Nasdaq consolidation is achieved.
U.S. Drug Enforcement Administration (DEA) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.